| Literature DB >> 33643535 |
Yosuke Tsuruga1, Toshiya Kamiyama2, Hirofumi Kamachi2, Tatsuya Orimo2, Shingo Shimada2, Akihisa Nagatsu2, Yoh Asahi2, Yuzuru Sakamoto2, Tatsuhiko Kakisaka2, Akinobu Taketomi2.
Abstract
BACKGROUND: Preoperative portal vein embolization (PVE) is a widely used strategy to enable major hepatectomy in patients with insufficient liver remnant. PVE induces hypertrophy of the future liver remnant (FLR) and a shift of the functional reserve to the FLR. However, whether the increase of the FLR volume (FLRV) corresponds to the functional transition after PVE remains unclear. AIM: To investigate the sequential relationship between the increase in FLRV and functional transition after preoperative PVE using 3-dimensional (3D) computed tomography (CT) and 99mTc-galactosyl-human serum albumin (99mTc-GSA) single-photon emission computed tomography (SPECT) fusion images.Entities:
Keywords: 99mTc-galactosyl-human serum albumin single-photon emission computed tomography; Fatty liver change; Functional transition; Future liver remnant volume; Hepatectomy; Preoperative portal vein embolization
Year: 2021 PMID: 33643535 PMCID: PMC7898185 DOI: 10.4240/wjgs.v13.i2.153
Source DB: PubMed Journal: World J Gastrointest Surg
Patient characteristics at baseline (n = 33)
|
|
|
| Age (yr), mean (range) | 67.7 (40-80) |
| Men/women | 20/13 |
| HBsAg positivity, | 3 (9.0) |
| HCV positivity, | 2 (6.1) |
| Diagnosis, | |
| Hilar cholangiocarcinoma | 20 (60.6) |
| Hepatoma | 6 (18.2) |
| Gallbladder cancer | 3 (9.1) |
| Intrahepatic cholangiocarcinoma | 2 (6.1) |
| Metastatic tumor | 2 (6.1) |
| Child-Pugh score (5/6/7/8), | 23/7/1/2 |
| Child-Pugh classification (A/B), | 30/3 |
| ICGR15 (%), mean (range) | 10.1 (1.5-33.2) |
| Preoperative biliary drainage, | 17 (51.5) |
| Initial resection ratio (%), mean ± SD | 64.5 ± 5.48 |
| Initial CT volume of FLR (mL), mean ± SD | 410.9 ± 79.4 |
| Average time between PVE and operation, d (range) | 30.0 (15-94) |
| Type of hepatectomy, | |
| Right hepatectomy + caudal lobectomy | 19 (57.6) |
| Right hepatectomy | 9 (27.3) |
| Left trisectionectomy + caudal lobectomy | 4 (12.1) |
| Left hepatectomy + caudal lobectomy | 1 (3.0) |
| Biliary reconstruction, | 24 (72.7) |
HBsAg: Hepatitis B virus surface antigen; HCV: Hepatitis C virus; ICGR15: Indocyanine green retention at 15 min; SD: Standard deviation; CT: Computed tomography; FLR: Future liver remnant; PVE: Portal vein embolization.
Figure 1Change in the volume of the future liver remnant after portal vein embolization. A: Change in the volume of the future liver remnant (FLR) after portal vein embolization in the whole case. FLR volume (FLRV) (dashed line) and functional FLRV (solid line); B: Change in the volume of the FLR after portal vein embolization in the group with preoperative biliary drainage; C: Change in the volume of the FLR after portal vein embolization in the group without preoperative biliary drainage. aP < 0.01. W: Week.
Comparison of the initial liver function, future liver remnant volume, and functional future liver remnant volume between the groups with and without preoperative biliary drainage
|
|
|
|
|
| ICGR15 (%), mean ± SD | 9.09 ± 5.0 | 11.2 ± 7.2 | 0.28 |
| Initial resection ratio (%), mean ± SD | 64.6 ± 6.36 | 64.4 ± 4.57 | 0.692 |
| Initial FLRV (mL), mean ± SD | 403.8 ± 88.6 | 418.4 ± 70.3 | 0.402 |
| Initial FFLRV (mL), mean ± SD | 366.4 ± 118.7 | 384.0 ± 92.7 | 0.601 |
| FLRV at 1 wk (mL), mean ± SD | 515.7 ± 100.9 | 515.0 ± 101.1 | 0.914 |
| FFLRV at 1 wk (mL), mean ± SD | 592 ± 114.0 | 583.0 ± 101.0 | 0.986 |
| FLRV at 2 wk (mL), mean ± SD | 550.1 ± 86.6 | 561.1 ± 114.5 | 0.958 |
| FFLRV at 2 wk (mL), mean ± SD | 640.0 ± 105.8 | 613.0 ± 96.6 | 0.382 |
ICGR15: Indocyanine green retention at 15 min; SD: Standard deviation; FLRV: Future liver remnant volume; FFLRV: Functional future liver remnant volume.
Figure 2Change in the difference between the future liver remnant volume and the functional future liver remnant volume after portal vein embolization. In three patients (solid lines), the functional future liver remnant volume became lower than the future liver remnant volume at 2 wk after portal vein embolization. W: Week.
Comparison of the background factors between the functional future liver remnant volume superior group and future liver remnant volume superior group
|
|
|
|
| Age (yr), mean ± SD | 67.4 ± 9.1 | 69.7 ± 9.5 |
| Gender | ||
| Male, | 18 (60.0) | 2 (66.7) |
| Female, | 12 (40.0) | 1 (33.3) |
| Body mass index (kg/m2), mean ± SD | 21.8 ± 3.5 | 23.4 ± 7.0 |
| Comorbidity ( | Diabetes (5), hypertension (3), dyslipidemia (1), COPD (1), alcoholism (1), angina (1), lacunar infarction (1) | Diabetes (1), fatty liver (1), alcoholism (1) |
| HBV/HCV infection ( | 3/1 | 0/1 |
| Child-Pugh score, mean ± SD | 5.4 ± 0.9 | 5.7 ± 0.6 |
| ICGR15 (%), mean ± SD | 10.4 ± 6.3 | 7.2 ± 2.0 |
| Initial resection ratio (%), mean ± SD | 64.3 ± 5.6 | 66.8 ± 4.4 |
| Initial FLRV (mL), mean ± SD | 405.4 ± 79.0 | 466.3 ± 73.2 |
Functional future liver remnant volume (FFLRV) superior group included the patients without FFLRV decrease below the future liver remnant volume (FLRV) at 2 wk after PVE. FLRV superior group included the patients with FFLRV decrease below the FLRV at 2 weeks after PVE. SD: Standard deviation; COPD: Chronic obstructive pulmonary disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ICGR15: Indocyanine green retention at 15 min; FLRV: Future liver remnant volume; FFLRV: Functional future liver remnant volume.
Figure 3Change in the difference between the future liver remnant volume and the functional future liver remnant volume after portal vein embolization and biopsy findings in patient 1. A: Change in future liver remnant volume (FLRV), functional FLRV (FFLRV), and future liver remnant (FLR) to spleen computed tomography (CT) attenuation ratio in patient 1. The FFLRV level remained below that of the FLRV at 2 wk after portal vein embolization (PVE). The decrease in the FLR to spleen CT attenuation ratio represents fatty changes in FLR at 5 wk after PVE; B: Biopsy findings in the FLR at 4 wk after PVE. The macro and micro-vesicular steatosis was more than 40%; C: At 13 wk after PVE, the steatosis had improved to approximately 10%. W: Week.